Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Supportive Care

Palifermin reduces infection rate and hyperfibrinogenemia in patients treated with high-dose chemotherapy based on beam or BU-thiothepa

Bone Marrow Transplantation volume 49, pages 1193–1197 (2014)Cite this article

Subjects

Abstract

We performed a retrospective study in patients who underwent high-dose chemotherapy and auto-SCT because of haematological malignancies. Forty patients were treated with palifermin while 80 were controls selected after being matched for diagnosis and length of neutropenia. Patients treated with BEAM or BU-CY or THIO-CY (BEAM/BUS) displayed, after palifermin, a lower rate of severe oral mucositis (P=0.03). This beneficial effect of palifermin was not evident in the stratum of patients treated with high-dose melphalan (HD-PAM). After palifermin, we observed in the whole treated population a reduced rate of ‘fever of unknown origin’ (FUO, P=0.02) and of severe infections not related to Gram-positive bacteria (FUO, Gram-negative bacteremia or pneumonia) (P=0.003). This effect of palifermin on infections not related to Gram-positive bacteria was evident only in patients receiving BEAM/BUS (P=0.01) and not in patients treated with HD-PAM (P=0.11). Fibrinogen peak in plasma was found to be reduced after palifermin in the whole population (P=0.01) and in the stratum who received BEAM/BUS (P=0.02) but not in the stratum of HD-PAM. In conclusion, anti-infectious beneficial effects of palifermin are more evident in BEAM/BUS-treated patients and toward some types of infections. Reduction of fibrinogen level after palifermin suggests that this agent reduces not only the rate of infections but also their severity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Gil L, Styczynski G, Komarnicki M . Infectious complication in 314 patients after high dose therapy and autologous hematopoietic stem cell transplantation: risk factor analysis and outcome. Infection 2007; 35: 421–427.

    Article  CAS  PubMed  Google Scholar 

  2. Kolbe K, Domkin D, Hg Derigs, Bhakdi S, Huber C, Aulitzky WE . Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation. Bone Marrow Transplant 1997; 19: 143–147.

    Article  CAS  PubMed  Google Scholar 

  3. Mossad SB, Longworth D, Goormastic M, Serkey JM, Keys TF, Bolwell BJ . Early infectious complications in autologous bone marrow transplantation: a review of 219 patients. Bone Marrow Transplant 1996; 18: 265–271.

    CAS  PubMed  Google Scholar 

  4. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al. Palifermin for oral mucositis afterintensive therapy for hematologic cancers. New Engl J Med 2004; 351: 2590–2598.

    Article  CAS  PubMed  Google Scholar 

  5. Tsirigotis P, Triantafyllou K, Girkas K, Giannopoulou V, Ioannidou E, Chondropoulos S et al. Keratinocyte growth factor is effective in theprevention of intestinal mucositis in patients with hematological malignanciestreated with high-dose chemotherapy and autologous hematopoietic SCT: a video-capsule endoscopy study. Bone Marrow Transplant 2008; 42: 337–343.

    Article  CAS  PubMed  Google Scholar 

  6. Nasilowska-Adamska B, Rzepecki P, Manko J, Czyz A, Markiewicz M, Federowicz I et al. The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant. Bone Marrow Transplant 2007; 40: 983–988.

    Article  CAS  PubMed  Google Scholar 

  7. Horsley P, Bauer JD, Mazkowiack R, Gardner R, Bashford J . Palifermin improves severe mucositis, swallowing problems, nutrition impact symptoms, and length of stay in patients undergoing hematopoietic stem cell transplantation. Support Care Cancer 2007; 15: 105–109.

    Article  PubMed  Google Scholar 

  8. Langner S, Staber P, Schub N, Gramatzki M, Grothe W, Behre G et al. Palifermin reduces incidence and severity oforal mucositis in allogeneic stem-cell transplant recipients. Bone Marrow Transplant 2008; 42: 275–279.

    Article  CAS  PubMed  Google Scholar 

  9. Herbers AH, van der Velden WJ, de Haan AF, Donnelly JP, Blijlevens NM . Impact of palifermin on intestinal mucositis of HSCT recipients after BEAM. Bone Marrow Transplant 2014; 49: 8–10.

    Article  CAS  PubMed  Google Scholar 

  10. Blijlevens N, de Château M, Krivan G, Rabitsch W, Szomor A, Pytlik R et al. In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden. Bone Marrow Transplant 2013; 48: 966–971.

    Article  CAS  PubMed  Google Scholar 

  11. Milone G, Leotta S, Pinto V, Avola G, Camuglia MG, Tripepi G . Palifermin in high dose chemotherapy and autologous stem cell transplantation reduces infection rate. Drugs Cell Ther Hematol 2013; 2: 133–146.

    Article  Google Scholar 

  12. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912–2919.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Donnelly JP, Muus P, Schattenberg A, De Witte T, Horrevorts A, De Pauw BE . A scheme for daily monitoring of oral mucositis in allogeneic BMT recipients. Bone Marrow Transplant 1992; 9: 409–413.

    CAS  PubMed  Google Scholar 

  14. Wardley AM, Jayson GC, Swindell R, Morgenstern GR, Chang J, Bloor R et al. Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol 2000; 110: 292–299.

    Article  CAS  PubMed  Google Scholar 

  15. Lissalde-Lavigne G, Combescure C, Muller L, Bengler C, Raillard A, Lefrant JY et al. Simple coagulation tests improve survival prediction in patients with septic shock. J Thromb Haemost 2008; 6: 645–653.

    Article  CAS  PubMed  Google Scholar 

  16. Wyleżoł I, Snarski E, Markiewicz M, Kyrcz-Krzemień S, Jędrzejczak WW, Walewski J . Comparison of benefits of early, delayed, and no administration of G-CSF after autologous peripheral blood stem cell transplantation in lymphoma patients. Ann Transplant 2013; 18: 336–341.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Programma di Trapianto Emopoietico, Azienda Ospedaliera Policlinico, Vittorio Emanuele, Catania, Italy

    G Milone, S Leotta, A Cupri, A L Fauci, P Spina, M Parisi & D Berritta

  2. CNR Epidemiology Unit, Reggio Calabria, Italy

    G Tripepi

Authors
  1. G Milone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Leotta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Cupri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A L Fauci
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P Spina
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Parisi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D Berritta
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G Tripepi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G Milone.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Milone, G., Leotta, S., Cupri, A. et al. Palifermin reduces infection rate and hyperfibrinogenemia in patients treated with high-dose chemotherapy based on beam or BU-thiothepa. Bone Marrow Transplant 49, 1193–1197 (2014). https://doi.org/10.1038/bmt.2014.140

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2014.140

This article is cited by

Search

Advanced search

Quick links